Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Immunotherapy With Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients With Chronic Immune Thrombocytopenic Purpura

NCT00547066 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00547066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00547066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Immunotherapy With Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients With Chronic Immune Thrombocytopenic Purpura
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2007
Completion date
November 30, 2011
Enrollment
48 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune thrombocytopenic purpura, purpura, thrombocytopenic, autoimmune, purpura, thrombocytopenic, idiopathic